Genmab As Stock Technical Analysis
| GNMSF Stock | USD 340.00 12.75 3.90% |
As of the 29th of January, Genmab A/S retains the Market Risk Adjusted Performance of 0.9195, downside deviation of 3.15, and Risk Adjusted Performance of 0.1295. Genmab A/S technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Genmab A/S jensen alpha, as well as the relationship between the potential upside and skewness to decide if Genmab A/S is priced fairly, providing market reflects its last-minute price of 340.0 per share. Given that Genmab AS has jensen alpha of 0.2905, we strongly advise you to confirm Genmab A/S's regular market performance to make sure the company can sustain itself at a future point.
Genmab A/S Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Genmab, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to GenmabGenmab |
Genmab A/S 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Genmab A/S's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Genmab A/S.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in Genmab A/S on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding Genmab AS or generate 0.0% return on investment in Genmab A/S over 90 days. Genmab A/S is related to or competes with WuXi Biologics, WuXi Biologics, Innovent Biologics, Sino Biopharmaceutica, Sino Biopharmaceutica, Astellas Pharma, and Astellas Pharma. Genmab AS develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark More
Genmab A/S Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Genmab A/S's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Genmab AS upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.15 | |||
| Information Ratio | 0.1372 | |||
| Maximum Drawdown | 10.42 | |||
| Value At Risk | (1.75) | |||
| Potential Upside | 3.9 |
Genmab A/S Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Genmab A/S's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Genmab A/S's standard deviation. In reality, there are many statistical measures that can use Genmab A/S historical prices to predict the future Genmab A/S's volatility.| Risk Adjusted Performance | 0.1295 | |||
| Jensen Alpha | 0.2905 | |||
| Total Risk Alpha | 0.1757 | |||
| Sortino Ratio | 0.0813 | |||
| Treynor Ratio | 0.9095 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Genmab A/S's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Genmab A/S January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1295 | |||
| Market Risk Adjusted Performance | 0.9195 | |||
| Mean Deviation | 1.18 | |||
| Semi Deviation | 1.25 | |||
| Downside Deviation | 3.15 | |||
| Coefficient Of Variation | 588.22 | |||
| Standard Deviation | 1.87 | |||
| Variance | 3.5 | |||
| Information Ratio | 0.1372 | |||
| Jensen Alpha | 0.2905 | |||
| Total Risk Alpha | 0.1757 | |||
| Sortino Ratio | 0.0813 | |||
| Treynor Ratio | 0.9095 | |||
| Maximum Drawdown | 10.42 | |||
| Value At Risk | (1.75) | |||
| Potential Upside | 3.9 | |||
| Downside Variance | 9.95 | |||
| Semi Variance | 1.57 | |||
| Expected Short fall | (2.32) | |||
| Skewness | (0.09) | |||
| Kurtosis | 2.53 |
Genmab A/S Backtested Returns
Genmab A/S appears to be very steady, given 3 months investment horizon. Genmab A/S holds Efficiency (Sharpe) Ratio of 0.17, which attests that the entity had a 0.17 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Genmab A/S, which you can use to evaluate the volatility of the firm. Please utilize Genmab A/S's Risk Adjusted Performance of 0.1295, market risk adjusted performance of 0.9195, and Downside Deviation of 3.15 to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Genmab A/S holds a performance score of 13. The company retains a Market Volatility (i.e., Beta) of 0.34, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Genmab A/S's returns are expected to increase less than the market. However, during the bear market, the loss of holding Genmab A/S is expected to be smaller as well. Please check Genmab A/S's sortino ratio, skewness, relative strength index, as well as the relationship between the potential upside and day median price , to make a quick decision on whether Genmab A/S's current trending patterns will revert.
Auto-correlation | 0.54 |
Modest predictability
Genmab AS has modest predictability. Overlapping area represents the amount of predictability between Genmab A/S time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Genmab A/S price movement. The serial correlation of 0.54 indicates that about 54.0% of current Genmab A/S price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.54 | |
| Spearman Rank Test | 0.53 | |
| Residual Average | 0.0 | |
| Price Variance | 84.34 |
Genmab A/S technical pink sheet analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, pink sheet market cycles, or different charting patterns.
Genmab A/S Technical Analysis
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Genmab A/S volatility. High ATR values indicate high volatility, and low values indicate low volatility.
About Genmab A/S Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Genmab AS on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Genmab AS based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Genmab A/S price pattern first instead of the macroeconomic environment surrounding Genmab A/S. By analyzing Genmab A/S's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Genmab A/S's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Genmab A/S specific price patterns or momentum indicators. Please read more on our technical analysis page.
Genmab A/S January 29, 2026 Technical Indicators
Most technical analysis of Genmab help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Genmab from various momentum indicators to cycle indicators. When you analyze Genmab charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1295 | |||
| Market Risk Adjusted Performance | 0.9195 | |||
| Mean Deviation | 1.18 | |||
| Semi Deviation | 1.25 | |||
| Downside Deviation | 3.15 | |||
| Coefficient Of Variation | 588.22 | |||
| Standard Deviation | 1.87 | |||
| Variance | 3.5 | |||
| Information Ratio | 0.1372 | |||
| Jensen Alpha | 0.2905 | |||
| Total Risk Alpha | 0.1757 | |||
| Sortino Ratio | 0.0813 | |||
| Treynor Ratio | 0.9095 | |||
| Maximum Drawdown | 10.42 | |||
| Value At Risk | (1.75) | |||
| Potential Upside | 3.9 | |||
| Downside Variance | 9.95 | |||
| Semi Variance | 1.57 | |||
| Expected Short fall | (2.32) | |||
| Skewness | (0.09) | |||
| Kurtosis | 2.53 |
Genmab A/S January 29, 2026 Daily Trend Indicators
Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as Genmab stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 0.00 | ||
| Daily Balance Of Power | Huge | ||
| Rate Of Daily Change | 1.04 | ||
| Day Median Price | 340.00 | ||
| Day Typical Price | 340.00 | ||
| Price Action Indicator | 6.38 |
Complementary Tools for Genmab Pink Sheet analysis
When running Genmab A/S's price analysis, check to measure Genmab A/S's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab A/S is operating at the current time. Most of Genmab A/S's value examination focuses on studying past and present price action to predict the probability of Genmab A/S's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab A/S's price. Additionally, you may evaluate how the addition of Genmab A/S to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |